Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

Hepatology (Baltimore, Md.) - 1 Apr 2005

Reiser Markus, Hinrichsen Holger, Benhamou Yves, Reesink Henk W, Wedemeyer Heiner, Avendano Cristina, Riba Neus, Yong Chan-Loi, Nehmiz Gerhard, Steinmann Gerhard G

Abstract excerpt

BILN-2061, a specific and potent peptidomimetic inhibitor of the HCV NS3 protease, has recently been shown to markedly lower serum hepatitis C virus (HCV)-RNA levels in patients chronically infected with HCV genotype 1 in three 2-day proof of principle studies. The aim of the current study was to assess the antiviral efficacy of BILN-2061 in patients with genotypes 2 and 3 HCV infection. The antiviral efficacy,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Drug Administration Schedule

Share to Macrocyclic Compounds

Share to Quinolines

Share to Serine Proteinase Inhibitors

Share to Thiazoles

Source

Identifiers

PMID: 15732092
DOI: 10.1002/hep.20612

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.PMID 15732092Read ↗

Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.Semantic proximity Read ↗

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.Semantic proximity Read ↗

Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment.Semantic proximity Read ↗

Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors.Semantic proximity Read ↗

HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism.Semantic proximity Read ↗

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.Semantic proximity Read ↗

Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.Semantic proximity Read ↗

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms.Semantic proximity Read ↗

Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.Semantic proximity Read ↗

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).Semantic proximity Read ↗

MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.Semantic proximity Read ↗

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.